Your Messages Inbox
Your Article Summary
See Latest ArticlesImmunoGen, Inc. Announces Exercise of Over-allotment Option
ImmunoGen, Inc., 06/23/09
ImmunoGen, Inc. , a biopharmaceutical company that develops targeted anticancer therapeutics, announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase 750,000 shares of common stock at a public offering price of $7.00 per share. The exercise of the over-allotment option brings the total shares of common stock to be sold by ImmunoGen in the offering to 5,750,000 shares.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
Abbott, 10/21/09
Myriad Genetics Acquires Exclusive Rights to Pancreatic Cancer Gene Patents From Johns Hopkins
Myriad, 10/16/09
Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09
Article Search
Sponsor